key: cord-0690133-dlaqcxox
authors: Ong, Samantha K.; Darji, Kavita; Chaudhry, Sofia B.
title: Severe flare of pemphigus vulgaris after first dose of COVID-19 vaccine
date: 2022-02-10
journal: JAAD Case Rep
DOI: 10.1016/j.jdcr.2022.01.027
sha: 5fff3c2b47c9457259b7a70361b860dac69c0576
doc_id: 690133
cord_uid: dlaqcxox

nan

Autoimmune bullous dermatoses encompass a variety of debilitating diseases with 51 serious sequelae that result from autoimmunity against intercellular adhesion molecules in the 52 skin or mucous membranes. Patients affected by these disorders are generally immunosuppressed 53 due to use of steroids and other immunomodulating medications. In the COVID-19 pandemic 54 era, these patients were encouraged to receive vaccination, as immunization seemed to be a safe 55 and effective way to prevent infection in this particularly vulnerable population (1) . To this date, 56 however, little is known about the efficacy and safety of the available COVID-19 vaccines in 57 patients affected by autoimmune bullous dermatoses. We present a case of a patient with 58 pemphigus vulgaris who received the first dose of COVID-19 vaccine during a period of 59 remission and subsequently experienced a disease flare. 

Literature-based immunization 165 recommendations for patients requiring immunosuppressive medications for autoimmune 166 bullous dermatoses

Development of 168 severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2 169

The first dose of COVID-19 vaccine may 172 trigger pemphigus and bullous pemphigoid flares: is the second dose therefore 173 contraindicated?

Exacerbation of pemphigus 176 foliaceus after tetanus vaccination accompanied by synthesis of auto-antibodies against 177 paraneoplastic pemphigus antigens

Exacerbation of pemphigus after influenza vaccination